The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Dexchlorpheniramine Market Research Report 2024

Global Dexchlorpheniramine Market Research Report 2024

Publishing Date : Feb, 2021

License Type :
 

Report Code : 1582414

No of Pages : 138

Synopsis
Dexchlorpheniramine (trade name Polaramine) is an antihistamine with anticholinergic properties used to treat allergic conditions such as hay fever or urticaria. It is the pharmacologically active dextrorotatory isomer of chlorpheniramine.

The global Dexchlorpheniramine market was valued at US$ XX million in 2019 and is expected to reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.
This report focuses on Dexchlorpheniramine volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Dexchlorpheniramine market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Dexchlorpheniramine Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Patent
Generic

Segment by Application
Antiallergic Agent
Histamine H₁-Receptor Antagonist

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
LETI
Novartis
Hypera Pharma
Woodward
Merck
Johnson and Johnson
Ethical Pharma
Gems Pharma
KPL Pharma
GlaxoSmithKline
Ying Yuan
Schering-Plough
Towa Yakuhin
Mantecorp FSA
Kalbe
Teva
Bayer
Mekophar
CFR Pharmaceuticals
Armoxindo Farma
Sawai Seiyaku
Pfizer
Instituto Sanitas
Caillon and Hamonet
Kobayashi Kako
Greater Pharma
Teuto Brasileiro
Harsen Laboratories
Index
1 Dexchlorpheniramine Market Overview
1.1 Product Overview and Scope of Dexchlorpheniramine
1.2 Dexchlorpheniramine Segment by Type
1.2.1 Global Dexchlorpheniramine Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Patent
1.2.3 Generic
1.3 Dexchlorpheniramine Segment by Application
1.3.1 Dexchlorpheniramine Sales Comparison by Application: (2021-2027)
1.3.2 Antiallergic Agent
1.3.3 Histamine H₁-Receptor Antagonist
1.4 Global Dexchlorpheniramine Market Size Estimates and Forecasts
1.4.1 Global Dexchlorpheniramine Revenue 2016-2027
1.4.2 Global Dexchlorpheniramine Sales 2016-2027
1.4.3 Dexchlorpheniramine Market Size by Region: 2016 Versus 2021 Versus 2027

2 Dexchlorpheniramine Market Competition by Manufacturers
2.1 Global Dexchlorpheniramine Sales Market Share by Manufacturers (2016-2021)
2.2 Global Dexchlorpheniramine Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Dexchlorpheniramine Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Dexchlorpheniramine Manufacturing Sites, Area Served, Product Type
2.5 Dexchlorpheniramine Market Competitive Situation and Trends
2.5.1 Dexchlorpheniramine Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Dexchlorpheniramine Players Market Share by Revenue
2.5.3 Global Dexchlorpheniramine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Dexchlorpheniramine Retrospective Market Scenario by Region
3.1 Global Dexchlorpheniramine Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Dexchlorpheniramine Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Dexchlorpheniramine Market Facts & Figures by Country
3.3.1 North America Dexchlorpheniramine Sales by Country
3.3.2 North America Dexchlorpheniramine Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Dexchlorpheniramine Market Facts & Figures by Country
3.4.1 Europe Dexchlorpheniramine Sales by Country
3.4.2 Europe Dexchlorpheniramine Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Dexchlorpheniramine Market Facts & Figures by Region
3.5.1 Asia Pacific Dexchlorpheniramine Sales by Region
3.5.2 Asia Pacific Dexchlorpheniramine Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Dexchlorpheniramine Market Facts & Figures by Country
3.6.1 Latin America Dexchlorpheniramine Sales by Country
3.6.2 Latin America Dexchlorpheniramine Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Dexchlorpheniramine Market Facts & Figures by Country
3.7.1 Middle East and Africa Dexchlorpheniramine Sales by Country
3.7.2 Middle East and Africa Dexchlorpheniramine Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Dexchlorpheniramine Historic Market Analysis by Type
4.1 Global Dexchlorpheniramine Sales Market Share by Type (2016-2021)
4.2 Global Dexchlorpheniramine Revenue Market Share by Type (2016-2021)
4.3 Global Dexchlorpheniramine Price by Type (2016-2021)

5 Global Dexchlorpheniramine Historic Market Analysis by Application
5.1 Global Dexchlorpheniramine Sales Market Share by Application (2016-2021)
5.2 Global Dexchlorpheniramine Revenue Market Share by Application (2016-2021)
5.3 Global Dexchlorpheniramine Price by Application (2016-2021)

6 Key Companies Profiled
6.1 LETI
6.1.1 LETI Corporation Information
6.1.2 LETI Description and Business Overview
6.1.3 LETI Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.1.4 LETI Product Portfolio
6.1.5 LETI Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Novartis Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Hypera Pharma
6.3.1 Hypera Pharma Corporation Information
6.3.2 Hypera Pharma Description and Business Overview
6.3.3 Hypera Pharma Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Hypera Pharma Product Portfolio
6.3.5 Hypera Pharma Recent Developments/Updates
6.4 Woodward
6.4.1 Woodward Corporation Information
6.4.2 Woodward Description and Business Overview
6.4.3 Woodward Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Woodward Product Portfolio
6.4.5 Woodward Recent Developments/Updates
6.5 Merck
6.5.1 Merck Corporation Information
6.5.2 Merck Description and Business Overview
6.5.3 Merck Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Merck Product Portfolio
6.5.5 Merck Recent Developments/Updates
6.6 Johnson and Johnson
6.6.1 Johnson and Johnson Corporation Information
6.6.2 Johnson and Johnson Description and Business Overview
6.6.3 Johnson and Johnson Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Johnson and Johnson Product Portfolio
6.6.5 Johnson and Johnson Recent Developments/Updates
6.7 Ethical Pharma
6.6.1 Ethical Pharma Corporation Information
6.6.2 Ethical Pharma Description and Business Overview
6.6.3 Ethical Pharma Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Ethical Pharma Product Portfolio
6.7.5 Ethical Pharma Recent Developments/Updates
6.8 Gems Pharma
6.8.1 Gems Pharma Corporation Information
6.8.2 Gems Pharma Description and Business Overview
6.8.3 Gems Pharma Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Gems Pharma Product Portfolio
6.8.5 Gems Pharma Recent Developments/Updates
6.9 KPL Pharma
6.9.1 KPL Pharma Corporation Information
6.9.2 KPL Pharma Description and Business Overview
6.9.3 KPL Pharma Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.9.4 KPL Pharma Product Portfolio
6.9.5 KPL Pharma Recent Developments/Updates
6.10 GlaxoSmithKline
6.10.1 GlaxoSmithKline Corporation Information
6.10.2 GlaxoSmithKline Description and Business Overview
6.10.3 GlaxoSmithKline Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.10.4 GlaxoSmithKline Product Portfolio
6.10.5 GlaxoSmithKline Recent Developments/Updates
6.11 Ying Yuan
6.11.1 Ying Yuan Corporation Information
6.11.2 Ying Yuan Dexchlorpheniramine Description and Business Overview
6.11.3 Ying Yuan Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Ying Yuan Product Portfolio
6.11.5 Ying Yuan Recent Developments/Updates
6.12 Schering-Plough
6.12.1 Schering-Plough Corporation Information
6.12.2 Schering-Plough Dexchlorpheniramine Description and Business Overview
6.12.3 Schering-Plough Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Schering-Plough Product Portfolio
6.12.5 Schering-Plough Recent Developments/Updates
6.13 Towa Yakuhin
6.13.1 Towa Yakuhin Corporation Information
6.13.2 Towa Yakuhin Dexchlorpheniramine Description and Business Overview
6.13.3 Towa Yakuhin Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Towa Yakuhin Product Portfolio
6.13.5 Towa Yakuhin Recent Developments/Updates
6.14 Mantecorp FSA
6.14.1 Mantecorp FSA Corporation Information
6.14.2 Mantecorp FSA Dexchlorpheniramine Description and Business Overview
6.14.3 Mantecorp FSA Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Mantecorp FSA Product Portfolio
6.14.5 Mantecorp FSA Recent Developments/Updates
6.15 Kalbe
6.15.1 Kalbe Corporation Information
6.15.2 Kalbe Dexchlorpheniramine Description and Business Overview
6.15.3 Kalbe Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.15.4 Kalbe Product Portfolio
6.15.5 Kalbe Recent Developments/Updates
6.16 Teva
6.16.1 Teva Corporation Information
6.16.2 Teva Dexchlorpheniramine Description and Business Overview
6.16.3 Teva Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.16.4 Teva Product Portfolio
6.16.5 Teva Recent Developments/Updates
6.17 Bayer
6.17.1 Bayer Corporation Information
6.17.2 Bayer Dexchlorpheniramine Description and Business Overview
6.17.3 Bayer Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.17.4 Bayer Product Portfolio
6.17.5 Bayer Recent Developments/Updates
6.18 Mekophar
6.18.1 Mekophar Corporation Information
6.18.2 Mekophar Dexchlorpheniramine Description and Business Overview
6.18.3 Mekophar Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.18.4 Mekophar Product Portfolio
6.18.5 Mekophar Recent Developments/Updates
6.19 CFR Pharmaceuticals
6.19.1 CFR Pharmaceuticals Corporation Information
6.19.2 CFR Pharmaceuticals Dexchlorpheniramine Description and Business Overview
6.19.3 CFR Pharmaceuticals Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.19.4 CFR Pharmaceuticals Product Portfolio
6.19.5 CFR Pharmaceuticals Recent Developments/Updates
6.20 Armoxindo Farma
6.20.1 Armoxindo Farma Corporation Information
6.20.2 Armoxindo Farma Dexchlorpheniramine Description and Business Overview
6.20.3 Armoxindo Farma Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.20.4 Armoxindo Farma Product Portfolio
6.20.5 Armoxindo Farma Recent Developments/Updates
6.21 Sawai Seiyaku
6.21.1 Sawai Seiyaku Corporation Information
6.21.2 Sawai Seiyaku Dexchlorpheniramine Description and Business Overview
6.21.3 Sawai Seiyaku Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.21.4 Sawai Seiyaku Product Portfolio
6.21.5 Sawai Seiyaku Recent Developments/Updates
6.22 Pfizer
6.22.1 Pfizer Corporation Information
6.22.2 Pfizer Dexchlorpheniramine Description and Business Overview
6.22.3 Pfizer Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.22.4 Pfizer Product Portfolio
6.22.5 Pfizer Recent Developments/Updates
6.23 Instituto Sanitas
6.23.1 Instituto Sanitas Corporation Information
6.23.2 Instituto Sanitas Dexchlorpheniramine Description and Business Overview
6.23.3 Instituto Sanitas Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.23.4 Instituto Sanitas Product Portfolio
6.23.5 Instituto Sanitas Recent Developments/Updates
6.24 Caillon and Hamonet
6.24.1 Caillon and Hamonet Corporation Information
6.24.2 Caillon and Hamonet Dexchlorpheniramine Description and Business Overview
6.24.3 Caillon and Hamonet Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.24.4 Caillon and Hamonet Product Portfolio
6.24.5 Caillon and Hamonet Recent Developments/Updates
6.25 Kobayashi Kako
6.25.1 Kobayashi Kako Corporation Information
6.25.2 Kobayashi Kako Dexchlorpheniramine Description and Business Overview
6.25.3 Kobayashi Kako Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.25.4 Kobayashi Kako Product Portfolio
6.25.5 Kobayashi Kako Recent Developments/Updates
6.26 Greater Pharma
6.26.1 Greater Pharma Corporation Information
6.26.2 Greater Pharma Dexchlorpheniramine Description and Business Overview
6.26.3 Greater Pharma Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.26.4 Greater Pharma Product Portfolio
6.26.5 Greater Pharma Recent Developments/Updates
6.27 Teuto Brasileiro
6.27.1 Teuto Brasileiro Corporation Information
6.27.2 Teuto Brasileiro Dexchlorpheniramine Description and Business Overview
6.27.3 Teuto Brasileiro Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.27.4 Teuto Brasileiro Product Portfolio
6.27.5 Teuto Brasileiro Recent Developments/Updates
6.28 Harsen Laboratories
6.28.1 Harsen Laboratories Corporation Information
6.28.2 Harsen Laboratories Dexchlorpheniramine Description and Business Overview
6.28.3 Harsen Laboratories Dexchlorpheniramine Sales, Revenue and Gross Margin (2016-2021)
6.28.4 Harsen Laboratories Product Portfolio
6.28.5 Harsen Laboratories Recent Developments/Updates

7 Dexchlorpheniramine Manufacturing Cost Analysis
7.1 Dexchlorpheniramine Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Dexchlorpheniramine
7.4 Dexchlorpheniramine Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Dexchlorpheniramine Distributors List
8.3 Dexchlorpheniramine Customers

9 Dexchlorpheniramine Market Dynamics
9.1 Dexchlorpheniramine Industry Trends
9.2 Dexchlorpheniramine Growth Drivers
9.3 Dexchlorpheniramine Market Challenges
9.4 Dexchlorpheniramine Market Restraints

10 Global Market Forecast
10.1 Dexchlorpheniramine Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Dexchlorpheniramine by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Dexchlorpheniramine by Type (2022-2027)
10.2 Dexchlorpheniramine Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Dexchlorpheniramine by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Dexchlorpheniramine by Application (2022-2027)
10.3 Dexchlorpheniramine Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Dexchlorpheniramine by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Dexchlorpheniramine by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
List of Tables
Table 1. Global Dexchlorpheniramine Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Dexchlorpheniramine Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global Dexchlorpheniramine Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Dexchlorpheniramine Covered in This Study
Table 5. Global Dexchlorpheniramine Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global Dexchlorpheniramine Sales Share by Manufacturers (2016-2021)
Table 7. Global Dexchlorpheniramine Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Dexchlorpheniramine Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Dexchlorpheniramine Average Price (US$/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Dexchlorpheniramine Manufacturing Sites and Area Served
Table 11. Manufacturers Dexchlorpheniramine Product Type
Table 12. Global Dexchlorpheniramine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Dexchlorpheniramine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dexchlorpheniramine as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Dexchlorpheniramine Sales by Region (2016-2021) & (K Units)
Table 16. Global Dexchlorpheniramine Sales Market Share by Region (2016-2021)
Table 17. Global Dexchlorpheniramine Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Dexchlorpheniramine Sales by Country (2016-2021) & (K Units)
Table 19. North America Dexchlorpheniramine Sales Market Share by Country (2016-2021)
Table 20. North America Dexchlorpheniramine Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Dexchlorpheniramine Revenue Market Share by Country (2016-2021)
Table 22. Europe Dexchlorpheniramine Sales by Country (2016-2021) & (K Units)
Table 23. Europe Dexchlorpheniramine Sales Market Share by Country (2016-2021)
Table 24. Europe Dexchlorpheniramine Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Dexchlorpheniramine Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Dexchlorpheniramine Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific Dexchlorpheniramine Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Dexchlorpheniramine Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Dexchlorpheniramine Revenue Market Share by Region (2016-2021)
Table 30. Latin America Dexchlorpheniramine Sales by Country (2016-2021) & (K Units)
Table 31. Latin America Dexchlorpheniramine Sales Market Share by Country (2016-2021)
Table 32. Latin America Dexchlorpheniramine Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Dexchlorpheniramine Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Dexchlorpheniramine Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa Dexchlorpheniramine Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Dexchlorpheniramine Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Dexchlorpheniramine Revenue Market Share by Country (2016-2021)
Table 38. Global Dexchlorpheniramine Sales (K Units) by Type (2016-2021)
Table 39. Global Dexchlorpheniramine Sales Market Share by Type (2016-2021)
Table 40. Global Dexchlorpheniramine Revenue (Million US$) by Type (2016-2021)
Table 41. Global Dexchlorpheniramine Revenue Share by Type (2016-2021)
Table 42. Global Dexchlorpheniramine Price (US$/Unit) by Type (2016-2021)
Table 43. Global Dexchlorpheniramine Sales (K Units) by Application (2016-2021)
Table 44. Global Dexchlorpheniramine Sales Market Share by Application (2016-2021)
Table 45. Global Dexchlorpheniramine Revenue (Million US$) by Application (2016-2021)
Table 46. Global Dexchlorpheniramine Revenue Share by Application (2016-2021)
Table 47. Global Dexchlorpheniramine Price (US$/Unit) by Application (2016-2021)
Table 48. LETI Corporation Information
Table 49. LETI Description and Business Overview
Table 50. LETI Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 51. LETI Dexchlorpheniramine Product
Table 52. LETI Recent Developments/Updates
Table 53. Novartis Corporation Information
Table 54. Novartis Description and Business Overview
Table 55. Novartis Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 56. Novartis Dexchlorpheniramine Product
Table 57. Novartis Recent Developments/Updates
Table 58. Hypera Pharma Corporation Information
Table 59. Hypera Pharma Description and Business Overview
Table 60. Hypera Pharma Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 61. Hypera Pharma Dexchlorpheniramine Product
Table 62. Hypera Pharma Recent Developments/Updates
Table 63. Woodward Corporation Information
Table 64. Woodward Description and Business Overview
Table 65. Woodward Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 66. Woodward Dexchlorpheniramine Product
Table 67. Woodward Recent Developments/Updates
Table 68. Merck Corporation Information
Table 69. Merck Description and Business Overview
Table 70. Merck Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 71. Merck Dexchlorpheniramine Product
Table 72. Merck Recent Developments/Updates
Table 73. Johnson and Johnson Corporation Information
Table 74. Johnson and Johnson Description and Business Overview
Table 75. Johnson and Johnson Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 76. Johnson and Johnson Dexchlorpheniramine Product
Table 77. Johnson and Johnson Recent Developments/Updates
Table 78. Ethical Pharma Corporation Information
Table 79. Ethical Pharma Description and Business Overview
Table 80. Ethical Pharma Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 81. Ethical Pharma Dexchlorpheniramine Product
Table 82. Ethical Pharma Recent Developments/Updates
Table 83. Gems Pharma Corporation Information
Table 84. Gems Pharma Description and Business Overview
Table 85. Gems Pharma Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 86. Gems Pharma Dexchlorpheniramine Product
Table 87. Gems Pharma Recent Developments/Updates
Table 88. KPL Pharma Corporation Information
Table 89. KPL Pharma Description and Business Overview
Table 90. KPL Pharma Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 91. KPL Pharma Dexchlorpheniramine Product
Table 92. KPL Pharma Recent Developments/Updates
Table 93. GlaxoSmithKline Corporation Information
Table 94. GlaxoSmithKline Description and Business Overview
Table 95. GlaxoSmithKline Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 96. GlaxoSmithKline Dexchlorpheniramine Product
Table 97. GlaxoSmithKline Recent Developments/Updates
Table 98. Ying Yuan Corporation Information
Table 99. Ying Yuan Description and Business Overview
Table 100. Ying Yuan Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 101. Ying Yuan Dexchlorpheniramine Product
Table 102. Ying Yuan Recent Developments/Updates
Table 103. Schering-Plough Corporation Information
Table 104. Schering-Plough Description and Business Overview
Table 105. Schering-Plough Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 106. Schering-Plough Dexchlorpheniramine Product
Table 107. Schering-Plough Recent Developments/Updates
Table 108. Towa Yakuhin Corporation Information
Table 109. Towa Yakuhin Description and Business Overview
Table 110. Towa Yakuhin Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 111. Towa Yakuhin Dexchlorpheniramine Product
Table 112. Towa Yakuhin Recent Developments/Updates
Table 113. Mantecorp FSA Corporation Information
Table 114. Mantecorp FSA Description and Business Overview
Table 115. Mantecorp FSA Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 116. Mantecorp FSA Dexchlorpheniramine Product
Table 117. Mantecorp FSA Recent Developments/Updates
Table 118. Kalbe Corporation Information
Table 119. Kalbe Description and Business Overview
Table 120. Kalbe Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 121. Kalbe Dexchlorpheniramine Product
Table 122. Kalbe Recent Developments/Updates
Table 123. Teva Corporation Information
Table 124. Teva Description and Business Overview
Table 125. Teva Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 126. Teva Dexchlorpheniramine Product
Table 127. Teva Recent Developments/Updates
Table 128. Bayer Corporation Information
Table 129. Bayer Description and Business Overview
Table 130. Bayer Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 131. Bayer Dexchlorpheniramine Product
Table 132. Bayer Recent Developments/Updates
Table 133. Mekophar Corporation Information
Table 134. Mekophar Description and Business Overview
Table 135. Mekophar Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 136. Mekophar Dexchlorpheniramine Product
Table 137. Mekophar Recent Developments/Updates
Table 138. CFR Pharmaceuticals Corporation Information
Table 139. CFR Pharmaceuticals Description and Business Overview
Table 140. CFR Pharmaceuticals Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 141. CFR Pharmaceuticals Dexchlorpheniramine Product
Table 142. CFR Pharmaceuticals Recent Developments/Updates
Table 143. Armoxindo Farma Corporation Information
Table 144. Armoxindo Farma Description and Business Overview
Table 145. Armoxindo Farma Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 146. Armoxindo Farma Dexchlorpheniramine Product
Table 147. Armoxindo Farma Recent Developments/Updates
Table 148. Sawai Seiyaku Corporation Information
Table 149. Sawai Seiyaku Description and Business Overview
Table 150. Sawai Seiyaku Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 151. Sawai Seiyaku Dexchlorpheniramine Product
Table 152. Sawai Seiyaku Recent Developments/Updates
Table 153. Pfizer Corporation Information
Table 154. Pfizer Description and Business Overview
Table 155. Pfizer Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 156. Pfizer Dexchlorpheniramine Product
Table 157. Pfizer Recent Developments/Updates
Table 158. Instituto Sanitas Corporation Information
Table 159. Instituto Sanitas Description and Business Overview
Table 160. Instituto Sanitas Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 161. Instituto Sanitas Dexchlorpheniramine Product
Table 162. Instituto Sanitas Recent Developments/Updates
Table 163. Caillon and Hamonet Corporation Information
Table 164. Caillon and Hamonet Description and Business Overview
Table 165. Caillon and Hamonet Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 166. Caillon and Hamonet Dexchlorpheniramine Product
Table 167. Caillon and Hamonet Recent Developments/Updates
Table 168. Kobayashi Kako Corporation Information
Table 169. Kobayashi Kako Description and Business Overview
Table 170. Kobayashi Kako Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 171. Kobayashi Kako Dexchlorpheniramine Product
Table 172. Kobayashi Kako Recent Developments/Updates
Table 173. Greater Pharma Corporation Information
Table 174. Greater Pharma Description and Business Overview
Table 175. Greater Pharma Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 176. Greater Pharma Dexchlorpheniramine Product
Table 177. Greater Pharma Recent Developments/Updates
Table 178. Teuto Brasileiro Corporation Information
Table 179. Teuto Brasileiro Description and Business Overview
Table 180. Teuto Brasileiro Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 181. Teuto Brasileiro Dexchlorpheniramine Product
Table 182. Teuto Brasileiro Recent Developments/Updates
Table 183. Harsen Laboratories Corporation Information
Table 184. Harsen Laboratories Description and Business Overview
Table 185. Harsen Laboratories Dexchlorpheniramine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 186. Harsen Laboratories Dexchlorpheniramine Product
Table 187. Harsen Laboratories Recent Developments/Updates
Table 188. Production Base and Market Concentration Rate of Raw Material
Table 189. Key Suppliers of Raw Materials
Table 190. Dexchlorpheniramine Distributors List
Table 191. Dexchlorpheniramine Customers List
Table 192. Dexchlorpheniramine Market Trends
Table 193. Dexchlorpheniramine Growth Drivers
Table 194. Dexchlorpheniramine Market Restraints
Table 195. Global Dexchlorpheniramine Sales Forecast by Type (2022-2027) & (K Units)
Table 196. Global Dexchlorpheniramine Sales Market Share Forecast by Type (2022-2027)
Table 197. Global Dexchlorpheniramine Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 198. Global Dexchlorpheniramine Revenue Market Share Forecast by Type (2022-2027)
Table 199. Global Dexchlorpheniramine Sales Forecast by Application (2022-2027) & (K Units)
Table 200. Global Dexchlorpheniramine Sales Market Share Forecast by Application (2022-2027)
Table 201. Global Dexchlorpheniramine Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 202. Global Dexchlorpheniramine Revenue Market Share Forecast by Application (2022-2027)
Table 203. Global Dexchlorpheniramine Sales Forecast by Region (2022-2027) & (K Units)
Table 204. Global Dexchlorpheniramine Sales Market Share Forecast by Region (2022-2027)
Table 205. Global Dexchlorpheniramine Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 206. Global Dexchlorpheniramine Revenue Market Share Forecast by Region (2022-2027)
Table 207. Research Programs/Design for This Report
Table 208. Key Data Information from Secondary Sources
Table 209. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Dexchlorpheniramine
Figure 2. Global Dexchlorpheniramine Market Share by Type in 2020 & 2027
Figure 3. Patent Product Picture
Figure 4. Generic Product Picture
Figure 5. Global Dexchlorpheniramine Market Share by Application in 2020 & 2027
Figure 6. Antiallergic Agent
Figure 7. Histamine H₁-Receptor Antagonist
Figure 8. Global Dexchlorpheniramine Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 9. Global Dexchlorpheniramine Market Size 2016-2027 (US$ Million)
Figure 10. Global Dexchlorpheniramine Sales 2016-2027 (K Units)
Figure 11. Global Dexchlorpheniramine Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 12. Dexchlorpheniramine Sales Share by Manufacturers in 2020
Figure 13. Global Dexchlorpheniramine Revenue Share by Manufacturers in 2020
Figure 14. The Global 5 and 10 Largest Dexchlorpheniramine Players: Market Share by Revenue in 2020
Figure 15. Dexchlorpheniramine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 16. Global Dexchlorpheniramine Sales Market Share by Region (2016-2021)
Figure 17. Global Dexchlorpheniramine Sales Market Share by Region in 2020
Figure 18. Global Dexchlorpheniramine Revenue Market Share by Region (2016-2021)
Figure 19. Global Dexchlorpheniramine Revenue Market Share by Region in 2020
Figure 20. U.S. Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 21. Canada Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 22. Germany Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 23. France Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. U.K. Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Italy Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Russia Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. China Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Japan Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. South Korea Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. India Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Australia Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Taiwan Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Indonesia Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Thailand Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Malaysia Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Philippines Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Vietnam Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Mexico Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Brazil Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Argentina Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Turkey Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Saudi Arabia Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. UAE Dexchlorpheniramine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Sales Market Share of Dexchlorpheniramine by Type (2016-2021)
Figure 45. Sales Market Share of Dexchlorpheniramine by Application (2016-2021)
Figure 46. Sales Market Share of Dexchlorpheniramine by Application in 2020
Figure 47. Revenue Share of Dexchlorpheniramine by Application (2016-2021)
Figure 48. Revenue Share of Dexchlorpheniramine by Application in 2020
Figure 49. Manufacturing Cost Structure of Dexchlorpheniramine
Figure 50. Manufacturing Process Analysis of Dexchlorpheniramine
Figure 51. Dexchlorpheniramine Industrial Chain Analysis
Figure 52. Channels of Distribution
Figure 53. Distributors Profiles
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’